Table 1 Patient characteristics and demographics
Variable | Single-agent No. (%) | Two-agent No. (%) | p-value |
|---|---|---|---|
Total patients | 100 | 68 | Â |
Age at diagnosis (years) | Â | Â | 0.037 |
Mean ± SD | 62.75 ± 7.80 | 58.32 ± 9.17 |  |
(Range) | (41–80) | (36–79) |  |
 ≥65 | 44(44) |  |  |
 < 65 | 56(56) | 21(31) | 0.087 |
| Â | Â | 47(69) | Â |
Sex | Â | Â | 0.717 |
 Male | 76(76) | 50(74) |  |
 Female | 24(24) | 18(26) |  |
Location | Â | Â | 0.479 |
 Cervical | 5(5) | 3(4) |  |
 Upper thoracic | 34(34) | 23(34) |  |
 Middle thoracic | 48(48) | 34(50) |  |
 Lower thoracic | 13(13) | 8(12) |  |
ECOG PS | Â | Â | 0.069 |
 0 | 30(30) | 32(47) |  |
 1 | 64(64) | 34(50) |  |
 2 | 6(6) | 2(3) |  |
Tumor stag | Â | Â | 0.896 |
 T1 | 10(10) | 8(12) |  |
 T2 | 38(38) | 22(32) |  |
 T3 | 31(31) | 23(34) |  |
 T4 | 21(21) | 15(22) |  |
Node stage | Â | Â | 0.360 |
 N0 | 56(56) | 31(46) |  |
 N1 | 24(24) | 18(26) |  |
 N2 | 20(20) | 19(28) |  |
Clinical stage | Â | Â | 0.814 |
 I | 24(24) | 15(22) |  |
 II | 44(44) | 28(41) |  |
 III | 32(32) | 25(37) |  |
Radiotherapy dose (Gy) | Â | Â | 0.21 |
Mean ± SD | 60.74 ± 3.46 | 61.97 ± 3.28 |  |
(Range) | (50–68) | (54–70) |  |
 > 60 | 26(26) | 26(38) | 0.092 |
 (50–60) | 74(74) | 42(62) |  |
Chemotherapy regimens | |||
 5-FU | 23(23) |  |  |
 Capecitabine | 10(10) |  |  |
 S-1 | 37(37) |  |  |
 Cisplatin | 25(25) |  |  |
 Nadeplatin | 5(5) |  |  |
 Paclitaxel + Cisplatin |  | 12(17) |  |
 Paclitaxel + carboplatin |  | 9(13) |  |
 Docetaxel+ Cisplatin |  | 6(9) |  |
 5-FU+ Cisplatin |  | 17(25) |  |
 5-FU+ Oxaliplatin |  | 5(7) |  |
 S-1 + Cisplatin |  | 12(18) |  |
 Capecitabine+ Cisplatin |  | 7(10) |  |